Stonepine Capital Management LLC Has $3.69 Million Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Stonepine Capital Management LLC raised its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 6.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,002 shares of the company’s stock after purchasing an additional 5,002 shares during the period. Establishment Labs makes up about 3.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 11th largest holding. Stonepine Capital Management LLC owned approximately 0.29% of Establishment Labs worth $3,686,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Strategic Wealth Partners Ltd. bought a new position in shares of Establishment Labs in the fourth quarter worth $1,874,000. Toronto Dominion Bank bought a new position in Establishment Labs in the 4th quarter valued at about $24,879,000. Redmile Group LLC raised its position in shares of Establishment Labs by 22.3% in the 4th quarter. Redmile Group LLC now owns 320,149 shares of the company’s stock valued at $14,749,000 after buying an additional 58,346 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Establishment Labs by 13.3% in the 4th quarter. Nuveen Asset Management LLC now owns 361,515 shares of the company’s stock valued at $16,655,000 after buying an additional 42,413 shares in the last quarter. Finally, Mudita Advisors LLP lifted its holdings in shares of Establishment Labs by 16.8% during the 4th quarter. Mudita Advisors LLP now owns 414,500 shares of the company’s stock worth $19,096,000 after acquiring an additional 59,699 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ESTA. Stephens reaffirmed an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. BTIG Research assumed coverage on Establishment Labs in a research report on Friday. They set a “buy” rating and a $62.00 price objective for the company. Finally, Needham & Company LLC upgraded Establishment Labs from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.33.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $36.16 on Friday. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $58.00. The stock’s 50 day moving average is $34.41 and its 200-day moving average is $38.21. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -14.02 and a beta of 0.73.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. During the same period in the previous year, the company posted ($0.58) EPS. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. Sell-side analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.